PD-L1 Expression in Non-Small Cell Lung Cancer: Data from a Referral Center in Spain

PD-L1 Expression in Non-Small Cell Lung Cancer: Data from a Referral Center in Spain

Anti-programmed cell death (PD1)/ligand-1 (PD-L1) checkpoint inhibitors have improved the survival of non-small cell lung cancer (NSCLC) patients. Additionally, PD-L1 has emerged as a predictive biomarker of response. Our goal was to examine the histological features of all PD-L1 cases of NSCLC anal...

Full description

Bibliographic Details
Main Authors:	Karmele Saez de Gordoa, Ingrid Lopez, Marta Marginet, Berta Coloma, Gerard Frigola, Naiara Vega, Daniel Martinez, Cristina Teixido
Format:	Article
Language:	English
Published:	MDPI AG 2021-08-01
Series:	Diagnostics
Subjects:	PD-L1 immunotherapy immunohistochemistry lung cancer NSCLC
Online Access:	https://www.mdpi.com/2075-4418/11/8/1452

Similar Items

Digital Pathology and PD-L1 Testing in Non Small Cell Lung Cancer: A Workshop Record
by: Fabio Pagni, et al.
Published: (2020-07-01)

rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC
by: Giovanna Polcaro, et al.
Published: (2024-03-01)

Radiomics combined with transcriptomics to predict response to immunotherapy from patients treated with PD-1/PD-L1 inhibitors for advanced NSCLC
by: Amine Bouhamama, et al.
Published: (2023-05-01)

Immunohistochemical expression of CD8, CTLA4, and PD-L1 in NSCLC of smokers versus non smokers and its effect on prognosis
by: Rasha. O. Elsaka, et al.
Published: (2022-12-01)

Role of sex and sex hormones in PD-L1 expression in NSCLC: clinical and therapeutic implications
by: Vianey Rodriguez-Lara, et al.
Published: (2023-10-01)

Fascaplysin Induces Apoptosis and Ferroptosis, and Enhances Anti-PD-1 Immunotherapy in Non-Small Cell Lung Cancer (NSCLC) by Promoting PD-L1 Expression
by: Lianxiang Luo, et al.
Published: (2022-11-01)

Erratum: Role of sex and sex hormones in PD-L1 expression in NSCLC: clinical and therapeutic implications
by: Frontiers Production Office
Published: (2024-01-01)

HLA class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC
by: Jie Mei, et al.
Published: (2022-07-01)

Atlas of PD-L1 for Pathologists: Indications, Scores, Diagnostic Platforms and Reporting Systems
by: Stefano Marletta, et al.
Published: (2022-06-01)

Sex difference in the expression of PD-1 of non-small cell lung cancer
by: Yong Gu, et al.
Published: (2022-10-01)

Prognostic Impact of PD-L1 Expression in pN1 NSCLC: A Retrospective Single-Center Analysis
by: Florian Eichhorn, et al.
Published: (2021-04-01)

Association between response to anti-PD-1 treatment and blood soluble PD-L1 and IL-8 changes in patients with NSCLC
by: Ling Yi, et al.
Published: (2023-03-01)

A multicenter, real‐world study on effectiveness and safety of first‐line modified PD‐1 inhibitors with chemotherapy in advanced non‐small cell lung cancer (aNSCLC) with drive gene‐negative
by: Tao Li, et al.
Published: (2024-02-01)

Non-small cell lung cancer patients treated with Anti-PD1 immunotherapy show distinct microbial signatures and metabolic pathways according to progression-free survival and PD-L1 status
by: David Dora, et al.
Published: (2023-12-01)

Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer
by: Diego de Miguel-Perez, et al.
Published: (2022-06-01)

Expression of PD-L1 Is Associated with Inflammatory Microenvironment in Surgical Specimens of Non-Small Cell Lung Cancer
by: Ivan Simundza, et al.
Published: (2021-08-01)

IL-17A promotes tumorigenesis and upregulates PD-L1 expression in non-small cell lung cancer
by: Hua Liao, et al.
Published: (2023-11-01)

Early response evaluation of PD-1 blockade in NSCLC patients through FDG-PET-CT and T cell profiling of tumor-draining lymph nodes
by: Frank J. Borm, et al.
Published: (2023-12-01)

PD-L1 Expression in Cutaneous Angiosarcomas: A Systematic Review with Meta-Analysis
by: Renato Lobrano, et al.
Published: (2023-05-01)

Expression of PD-L1 in Malignant Soft Tissue Neoplasm and Their Correlation with Clinicopathological Parameters
by: Ashutosh Mishra, et al.

Study of PD-L1 Expression in Tumours Based on Site and Histology of Tumour – The Experience of a Tertiary Referral Laboratory
by: Vinita Pant, et al.
Published: (2023-04-01)

Differentially Expressed Genes Involved in Primary Resistance to Immunotherapy in Patients with Advanced-Stage Pulmonary Cancer
by: Luis Miguel Chinchilla-Tábora, et al.
Published: (2024-02-01)

Complete response to pembrolizumab as a single agent in a patient with stage III NSCLC with high PD-L1 expression: a case report
by: Paola Maria Medusa, et al.
Published: (2022-11-01)

PD-L1 testing by immunohistochemistry in immuno-oncology
by: Semir Vranic, et al.
Published: (2023-01-01)

Effectiveness and Safety of Anlotinib Combined with PD-1 Blockades in Patients with Previously Immunotherapy Treated Advanced Non-Small Cell Lung Cancer: A Retrospective Exploratory Study
by: Dou XJ, et al.
Published: (2024-03-01)

The association of genomic alterations with PD‐L1 expression in Chinese patients with EGFR/ALK wild‐type lung adenocarcinoma and potential predictive value of Hippo pathway mutations to immunotherapy
by: Fangfang Liu, et al.
Published: (2024-02-01)

Presence of Akkermansiaceae in gut microbiome and immunotherapy effectiveness in patients with advanced non-small cell lung cancer
by: Anna Grenda, et al.
Published: (2022-07-01)

Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors
by: Melanie Janning, et al.
Published: (2019-06-01)

Clinical efficacy and safety of anti-PD-1/PD-L1 treatments in non-small cell lung cancer (NSCLC)
by: Tian Zeng, et al.
Published: (2019-12-01)

Expression of PD-1, PD-L1 and PD-L2 in Lymphomas in Patients with Pre-Existing Rheumatic Diseases—A Possible Association with High Rheumatoid Arthritis Disease Activity
by: Erik Hellbacher, et al.
Published: (2022-03-01)

PD-1+ IFN-γ+ subset of CD8+ T cell in circulation predicts response to anti–PD-1 therapy in NSCLC
by: Wenxiu Chen, et al.
Published: (2023-06-01)

Targeting the ERβ/HER Oncogenic Network in <i>KRAS</i> Mutant Lung Cancer Modulates the Tumor Microenvironment and Is Synergistic with Sequential Immunotherapy
by: Abdulaziz A. Almotlak, et al.
Published: (2021-12-01)

Experience of treatment of a patient with non-small cell lung cancer with met exon 14 skipping
by: M. O. Mandrina, et al.
Published: (2021-08-01)

Brief Report: A Blood-Based MicroRNA Complementary Diagnostic Predicts Immunotherapy Efficacy in Advanced-Stage NSCLC With High Programmed Death-Ligand 1 Expression
by: Timothy Rajakumar, MD, PhD, et al.
Published: (2022-08-01)

Investigation of the PD-1/PD-L1 Expression in the Lesional Skins of Patients with Psoriasis
by: Selma Emre, et al.
Published: (2023-04-01)

<sup>18</sup>F-FDG Pet Parameters and Radiomics Features Analysis in Advanced Nsclc Treated with Immunotherapy as Predictors of Therapy Response and Survival
by: Giulia Polverari, et al.
Published: (2020-05-01)

Current Immunotherapeutic Strategies Targeting the PD-1/PD-L1 Axis in Non-Small Cell Lung Cancer with Oncogenic Driver Mutations
by: Ichidai Tanaka, et al.
Published: (2021-12-01)

The landscape of immune microenvironment in lung adenocarcinoma and squamous cell carcinoma based on PD‐L1 expression and tumor‐infiltrating lymphocytes
by: Lu Chen, et al.
Published: (2019-12-01)

PD-L1 Status in Tenosynovial Giant Cell Tumors
by: Tulay Zenginkinet, et al.
Published: (2022-09-01)

PD‐L1 expressed from tumor cells promotes tumor growth and invasion in lung cancer via modulating TGF‐β1/SMAD4 expression
by: Ming‐Jenn Chen, et al.
Published: (2022-05-01)